News

pharmaphorum19h
Moderna's RSV shot gets US nod for use in younger adults
Pfizer's RSV shot Abrysvo was cleared by the FDA last October for the 18 to 59 age group, extending its 2023 approval in the ...
The Pharma Letter17h
FDA nod for Moderna’s RSV Vaccine, mRESVIA for younger adults
US mRNA specialist Moderna today announced that the US Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), ...